193 followers
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). https://t.co/GhdR7JIMSa https://t.co/PT8KMtt4